Latest property, plant & equipment for ECTE: $190K.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
The latest PP&E for ECTE is $190K as of September 2016. That compares with $300K in the prior-year period — down 37.4% year over year. Investors often review this figure alongside Echo Therapeutics's historical trend and sector peers before judging valuation or financial health.
Over the past year, ECTE's PP&E moved from $300K to $190K — a 37.4% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Echo Therapeutics's operating scale or balance-sheet position.
A PP&E figure of $190K for ECTE is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.
After noting ECTE's PP&E ($190K), review year-over-year change from $300K, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.